- France
- /
- Medical Equipment
- /
- ENXTPA:ALMKT
What Mauna Kea Technologies SA's (EPA:ALMKT) 31% Share Price Gain Is Not Telling You
The Mauna Kea Technologies SA (EPA:ALMKT) share price has done very well over the last month, posting an excellent gain of 31%. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 22% over that time.
Since its price has surged higher, given close to half the companies operating in France's Medical Equipment industry have price-to-sales ratios (or "P/S") below 2x, you may consider Mauna Kea Technologies as a stock to potentially avoid with its 2.9x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified.
See our latest analysis for Mauna Kea Technologies
How Has Mauna Kea Technologies Performed Recently?
Recent times have been advantageous for Mauna Kea Technologies as its revenues have been rising faster than most other companies. It seems the market expects this form will continue into the future, hence the elevated P/S ratio. However, if this isn't the case, investors might get caught out paying too much for the stock.
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Mauna Kea Technologies.What Are Revenue Growth Metrics Telling Us About The High P/S?
The only time you'd be truly comfortable seeing a P/S as high as Mauna Kea Technologies' is when the company's growth is on track to outshine the industry.
If we review the last year of revenue growth, the company posted a terrific increase of 36%. The latest three year period has also seen an excellent 52% overall rise in revenue, aided by its short-term performance. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.
Turning to the outlook, the next three years should bring diminished returns, with revenue decreasing 5.0% per year as estimated by the only analyst watching the company. That's not great when the rest of the industry is expected to grow by 6.0% each year.
In light of this, it's alarming that Mauna Kea Technologies' P/S sits above the majority of other companies. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. Only the boldest would assume these prices are sustainable as these declining revenues are likely to weigh heavily on the share price eventually.
What We Can Learn From Mauna Kea Technologies' P/S?
Mauna Kea Technologies shares have taken a big step in a northerly direction, but its P/S is elevated as a result. Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
For a company with revenues that are set to decline in the context of a growing industry, Mauna Kea Technologies' P/S is much higher than we would've anticipated. Right now we aren't comfortable with the high P/S as the predicted future revenue decline likely to impact the positive sentiment that's propping up the P/S. Unless these conditions improve markedly, it'll be a challenging time for shareholders.
You need to take note of risks, for example - Mauna Kea Technologies has 6 warning signs (and 2 which are significant) we think you should know about.
Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About ENXTPA:ALMKT
Mauna Kea Technologies
A medical device company, manufactures and sells medical devices in Europe and internationally.
Medium-low and slightly overvalued.